NASDAQ · ZLAB
Healthcare · Biotechnology
$25.57
Down-$0.07 (-0.27%)
Updated Aug 19, 2026, 7:09 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ZLAB closed at $25.57 after 21 trading sessions, up 24.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $24.86 | $25.62 | $24.64 | $25.57 | 1.63M |
| Aug 17, 2026 | $25.25 | $25.92 | $24.77 | $25.64 | 1.36M |
| Aug 14, 2026 | $25.44 | $26.26 | $25.33 | $25.90 | 1.23M |
| Aug 13, 2026 | $26.21 | $26.382 | $25.70 | $26.03 | 1.04M |
| Aug 12, 2026 | $25.00 | $25.77 | $25.00 | $25.49 | 2.18M |
| Aug 11, 2026 | $23.54 | $26.66 | $23.54 | $26.00 | 3.81M |
| Aug 10, 2026 | $22.57 | $23.64 | $22.505 | $23.57 | 1.7M |
| Aug 7, 2026 | $21.96 | $24.065 | $21.5786 | $23.32 | 2.05M |
| Aug 6, 2026 | $19.05 | $21.80 | $18.845 | $20.88 | 1.39M |
| Aug 5, 2026 | $18.51 | $18.535 | $18.22 | $18.37 | 195.28K |
| Aug 4, 2026 | $18.39 | $18.78 | $18.31 | $18.49 | 290.55K |
| Aug 3, 2026 | $18.30 | $18.44 | $18.15 | $18.18 | 324.31K |
| Jul 31, 2026 | $18.23 | $18.77 | $17.97 | $18.27 | 353.71K |
| Jul 30, 2026 | $18.28 | $18.30 | $17.92 | $18.21 | 332.77K |
| Jul 29, 2026 | $18.33 | $18.53 | $18.10 | $18.31 | 577.61K |
| Jul 28, 2026 | $18.87 | $19.175 | $18.26 | $18.62 | 1.14M |
| Jul 27, 2026 | $19.14 | $19.31 | $18.55 | $18.64 | 708.64K |
| Jul 24, 2026 | $19.46 | $19.52 | $18.92 | $19.22 | 478.12K |
| Jul 23, 2026 | $20.30 | $20.52 | $19.66 | $19.68 | 660.43K |
| Jul 22, 2026 | $20.66 | $20.85 | $20.455 | $20.50 | 248.42K |
| Jul 21, 2026 | $20.36 | $20.898 | $20.19 | $20.48 | 770.73K |
The latest Smart Investors Daily articles mentioning ZLAB.
ZLAB research
Company profile and research snapshot.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2020 | SVB Leerink | Outperform | — |
| Dec 30, 2019 | Citigroup | Buy | — |
| Sep 4, 2019 | China Renaissance | Buy | — |
| Jul 5, 2019 | Macquarie | Outperform | — |
| Jan 29, 2019 | Credit Suisse | Outperform | — |
No generated briefing is available yet.
Yahoo · Aug 7, 2026
Zai Lab (NASDAQ:ZLAB) said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business. Founder, Chairperson and CEO Samantha Du said the company is advanc
Benzinga · Aug 7, 2026
Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the price target from $44 to $45.
Yahoo · Aug 6, 2026
Zai Lab Ltd (ZLAB) advances its DLL3 ADC pipeline with three registrational programs expected by year-end, while navigating a strategic shift toward global expansion over near-term profitability.
SeekingAlpha · Aug 6, 2026
Zai Lab Limited (ZLAB) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsChristine Chiou - Senior VP & Head of Investor RelationsYing...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZLAB.
